Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) - GSK

Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) - Merck (MSD)

Cervarix (recombinant human papillomavirus bivalent vaccine) - GSK, Japan Vaccine

Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) - Sanofi

Daptacel (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) - Sanofi

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (clinicaltrials.gov) - Oct 22, 2026 - P4 | N=5000 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Jan 2028 | Trial primary completion date: Sep 2026 ➔ Jan 2027
Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

http://clinicaltrials.gov/ct2/show/NCT05237947

Oct 22, 2026